BRIEF published on 11/10/2025 at 07:05, 25 days ago L'étude de phase 2B BV100 de BioVersys est prévue pour l'Asie Essai De Phase 2b Résistance Aux Médicaments BioVersys BV100 Financement Wellcome Réseau ADVANCE-ID
BRIEF published on 11/10/2025 at 07:05, 25 days ago BioVersys' BV100 Phase 2B Study Set for Asia Phase 2B Trial Drug Resistance BioVersys BV100 Wellcome Funding ADVANCE-ID Network
PRESS RELEASE published on 11/10/2025 at 07:00, 25 days ago BioVersys BV100 Phase 2B to be conducted via Wellcome Funded Trial Network BioVersys BV100 Phase 2B to be conducted via Wellcome Funded Trial Network. BioVersys AG leads Phase 2 trial for innovative antibacterial product BV100 Phase 2b Clinical Trial BV100 BioVersys Wellcome Funded Trial Network
BRIEF published on 11/06/2025 at 07:05, 29 days ago BioVersys fait progresser les essais cliniques du BV100 en Chine Essais Cliniques BV100 BioVersys Bactéries Multirésistantes Acinetobacter
BRIEF published on 11/06/2025 at 07:05, 29 days ago BioVersys Advances BV100 Clinical Trials in China Clinical Trials BV100 BioVersys MDR Bacteria Acinetobacter
PRESS RELEASE published on 11/06/2025 at 07:00, 29 days ago Bioversys ANNOUNCES FIRST SUBJECTS DOSED IN PHASE 1 CLINICAL TRIAL OF BV100 in CHInA BioVersys announces the dosing of the first subject in a Phase 1 clinical trial with BV100 in China. BV100 targets MDR hospital infections caused by Acinetobacter baumannii Phase 1 Clinical Trial BV100 BioVersys MDR Bacteria Acinetobacter Baumannii
BRIEF published on 11/05/2025 at 07:05, 1 month ago BioVersys to Present at Stifel 2025 Annual Healthcare Conference New York City Healthcare Conference Clinical Developments BioVersys Multi-drug Resistant Bacteria
BRIEF published on 11/05/2025 at 07:05, 1 month ago BioVersys présentera ses travaux lors de la conférence annuelle Stifel 2025 sur les soins de santé. New York Conférence Sur Les Soins De Santé BioVersys Développements Cliniques Bactéries Multirésistantes
PRESS RELEASE published on 11/05/2025 at 07:00, 1 month ago Bioversys to Present at Stifel 2025 Annual Healthcare Conference in New york BioVersys AG will present at Stifel 2025 Annual Healthcare Conference in New York, showcasing latest clinical and preclinical developments. Key focus on antibacterial products for MDR bacteria Healthcare Conference BioVersys AG Antibacterial Products MDR Bacteria Stifel 2025
BRIEF published on 11/03/2025 at 07:05, 1 month 2 days ago BioVersys Appoints Dr. Daniel Ritz as Chief Scientific Officer Chief Scientific Officer BioVersys MDR Bacteria Dr. Daniel Ritz Anti-infective
Published on 12/05/2025 at 02:35, 4 hours 56 minutes ago Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 01:00, 6 hours 31 minutes ago BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 8 hours 26 minutes ago BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 8 hours 31 minutes ago NXT Energy Solutions Completes Data Acquisition for SFD Survey
Published on 12/05/2025 at 07:00, 31 minutes ago Swiss Re targets a net income of USD 4.5 billion in 2026; refreshed strategy to strengthen core business
Published on 12/05/2025 at 03:30, 4 hours 1 minute ago CGTN: What makes cooperation between China and France a two-way success
Published on 12/04/2025 at 23:50, 7 hours 40 minutes ago EQS-Adhoc: Dexus Finance Pty Limited: Dexus prices A$500 million of subordinated notes
Published on 12/04/2025 at 20:25, 11 hours 6 minutes ago Newmark Appoints Globally Recognized Real Estate Executive Peter Trollope to Lead Occupier Solutions
Published on 12/04/2025 at 20:15, 11 hours 16 minutes ago Galimedix Therapeutics presents compelling Phase 1 study results showing excellent safety and pharmacokinetics with oral small molecule GAL-101 at CTAD 2025
Published on 12/04/2025 at 18:14, 13 hours 17 minutes ago Résiliation d'une convention conclue entre actionnaires
Published on 12/04/2025 at 18:00, 13 hours 31 minutes ago Informations relatives au nombre total de droits de vote et d’actions composant le capital social au 28 novembre 2025
Published on 12/04/2025 at 18:00, 13 hours 31 minutes ago Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 13 hours 46 minutes ago Informations relatives au nombre total de droits de vote et d’actions
Published on 12/04/2025 at 17:45, 13 hours 46 minutes ago MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
